The universal field hypothesis of catatonia and neuroleptic malignant syndrome

CNS Spectrums

Volumn 5, Issue 7, 2000, Pages 26-33

  Carroll, B T ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; AMANTADINE; APTIGANEL; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; BULBOCAPNINE; DOPAMINE; DOPAMINE 2 RECEPTOR; FLUMAZENIL; FLUOXETINE; GLUTAMIC ACID; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PHENCYCLIDINE; SEROTONIN; SEROTONIN 1A RECEPTOR; ZOLPIDEM;

ARTICLE; CATATONIA; HUMAN; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; PRIORITY JOURNAL;

EID: 0033861043     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900013365     Document Type: Article

References (51)

1. Disturbances of somatic function in catatonia with a periodic course and their compensation
2. Catatonia and the neuroleptics: Psychobiologic significance of remote and recent findings
3. Disturbances of consciousness with lesions of the brain-stem and diencephalon
4. The catatonic syndrome
5. Where have all the catatonics gone?
6. Basal ganglia and movement disorders: An update
7. The neuroleptic malignant syndrome
8. Catatonic syndrome in a general psychiatric inpatient population: Frequency, clinical presentation, and response to lorazepam
9. Catatonia II. Treatment with Lorazepam and Electroconvulsive Therapy
10. Benzodiazepines in the treatment of catatonic syndromes
11. Catatonia: Re-awakening to a forgotten disorder
12. Catatonia-like events after valproic acid with risperidone and sertraline
13. Das maligne neurolepticsche Syndrome (MNS)-Diagnose, Therapie und Pathogenese
14. Catatonia
15. Neuroleptic malignant syndrome and catatonia: One entity or two?
16. The nondichotomy between lethal catatonia and neuroleptic malignant syndrome
17. Catatonic signs in neuroleptic malignant syndrome
18. Catatonia and the neuroleptic malignant syndrome
19. 17 Catatonic Patients Diagnosed as Neuroleptic Malignant Syndrome
20. Catatonic disorder due to general medical conditions
21. Lorazepam treatment of psychogenic catatonia: An update
22. A consideration of the mechanisms by which lorazepam might treat catatonia
23. Stupor and affective status: Alleviation of the psychotmotor disturbances by lorazepam and recurrence of symptoms after Ro 15-1788
24. Catatonia after benzodiazepine withdrawal
25. Lorazepam for chronic catatonia: A randomized, double-blind, placebo controlled cross-over study
26. The GABA(A) versus GABA(B) hypothesis of catatonia
27. Zolpidem in catatonic syndrome: From a pharmacological test to a pathophysiological hypothesis
28. Akinetic mutism after baclofen
29. Zolpidem in Parkinson's disease
30. Zolpidem in progressive supranuclear palsy (letter)
31. Lorazepam treatment of neuroleptic malignant syndrome
32. The future of antipsychotic drug therapy: Current atypical agents and beyond
33. (3H) WAY-100635 for 5-HT1A receptor autoradiography in human brain: A comparison with (3H)-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia
34. 5-HT1A and 5-HT2A receptor mRNAs abd binding site densities are differentially altered in schizophrenia
35. The cataleptogenic effects of the neuroleptic nemonapride are attenuated by its 5-HT1A receptor agonist properties
36. 5-HT1A receptor agonist properties of the antipsychotic, nemonapride: Comparison with bromerguride and clozapine
37. Glutamate receptor dysfunction and schizophrenia
38. Acute phencyclidine intoxication: Clinical patterns, complications, and treatment
39. Recent advances in the phencyclidine model of schizophrenia
40. Cerestat and other NMDA antagonists in ischemic stroke
41. Glutamanergic dysfunction in catatonia? Successful treatment of three acute akinetic catatonic patients with NMDA antagonist amantidine
42. Effect of mematine (NMDA antagonist) in Parkinson's disease: A double-blind cross-over randomized study